Download IMMUNOPULSE aims to stimulate the body`s immune system in

ONCOSEC
Investor Information Package
IMMUNOPULSE aims
to stimulate the body’s
immune system in order
to target and eliminate
cancerous cells.
If you’d like to discuss
investment opportunities
please contact us directly:
Address —
9810 Summers Ridge Road
Suite 110
San Diego CA 92121
Telephone —
+1 855 662 6732
Email —
[email protected]
Website —
www.OncoSec.com
BENEFITS
Administered in an outpatient setting.
Electroporation increase uptake by up to 4000x
Clinicians can combine with other therapeutic approaches
Uses body’s own immune system to target and eliminate cancer
May trigger a systemic response that reaches cancer cells
beyond the treatment area
WHERE DOES IMMUNOPULSE FIT?
STAGE 1
STAGE II
STAGE
111 A
STAGE
111 B
STAGE
111 C
STAGE
IV M1A
STAGE
IV M1B
STAGE
IV M1C
SURGERY
RADIATION
YERVOY/ZELBORAF
CHEMOTHERAPY
IMMUNOPULSE
Cancer cells
surrounded by
healthy cells.
4
During brief electroporation
DNA-IL12 enters
and starts to produce IL-12.
3
2
1
DNA IL-12
(a gene based
immune trigger)
is injected into tumor.
Use electroporation to
open microscopic pores
in cell membrane, allowing
the agent to enter.
6
5
IL-12 is produced, eliciting
an immune response which
enables the body to identify
and kill cancerous cells.
Cancerous cells now are
detected as a result of the
immune response. These
cells are now a target to kill.
7
Studies to date have
shown a systemic response
(reduction in untreated
tumors)
METASTATIC MELANOMA STUDY | DNA IL-12
MOFFITT CANCER CENTRE
— 24 Patients
1st human study using elctro-gene therapy
76%
of lesions showed
>20% reduction
in size
53%
of patients
showed objective
response*
16%
of patients
showed complete
remission
P HA S E I — ME L A NO MA DATA
P HA S E I I — I N T E R I M ME L A NO MA DATA
61%
of patients showed
systemic
response
48%
of patients showed
objective
response*
MULTI-CENTER
10%
of patients showed
complete
remission
— 21 Patients
A total of 47 patients (Phase I & Phase II) have been treated to date
without a single, drug-related serious adverse event.
*includes stable disease
ONCOSEC FINANCIALS
Shares Outstanding
Warrants
Stock Options
183,494,299
67,749,301
6,659,500
EXCHANGE/SYMBOL: OTCQB : ONCS
A N A LY S T C O V E R A G E
NOBLE FINANCIAL
MAXIM GROUP
ONCOSEC IN THE MEDIA
H.C. WAINRIGHT